Drugs / HLX71
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04583228 | Apr → Jul 2021 | COVID-19 | Hengenix Biotech Inc | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-11-06 | Shanghai Henlius Biotech | Regulatory Henlius ACE2-Fc Fusion Protein HLX71 Received IND Approval from US FDA henlius.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-04-14 | Shanghai Henlius Biotech | First Subject Dosed in Phase 1 Clinical Trial of Henlius COVID-19 Drug Candidate HLX71 in the US henlius.com ↗ |
| 2020-11-06 | Shanghai Henlius Biotech | Henlius ACE2-Fc Fusion Protein HLX71 Received IND Approval from US FDA henlius.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX71 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04583228 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein” NCT04583228 ↗ |
| Route | Intravenous | “Single-dose, intravenous infusion” NCT04583228 ↗ |